Wada Satoshi, Yada Erika, Ohtake Junya, Fujimoto Yuki, Uchiyama Hidemi, Yoshida Shintaro, Sasada Tetsuro
Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
Immunotherapy. 2016 Nov;8(11):1321-1333. doi: 10.2217/imt-2016-0063.
Cancer immunotherapy has attracted attention worldwide owing to the recent development of immune checkpoint inhibitors. However, these therapies have shown limited efficacy, and further advancements are needed before these modalities can progress to widespread use. Immune checkpoint inhibitors are a type of nonspecific cancer immunotherapy, and antitumor effects are only observed when cancer-specific T cells are found within the nonspecifically activated T-cell group. In order to facilitate the development of potent immunotherapies, selective enhancement of cancer-specific T cells is essential. In this report, we discuss current and future perspectives, including the latest clinical trials of cancer-specific immunotherapies, particularly cancer peptide vaccines.
由于免疫检查点抑制剂的近期发展，癌症免疫疗法已引起全球关注。然而，这些疗法的疗效有限，在这些方法能够广泛应用之前，还需要进一步发展。免疫检查点抑制剂是一种非特异性癌症免疫疗法，只有在非特异性激活的T细胞群体中发现癌症特异性T细胞时，才会观察到抗肿瘤作用。为了促进有效的免疫疗法的发展，选择性增强癌症特异性T细胞至关重要。在本报告中，我们讨论了当前和未来的前景，包括癌症特异性免疫疗法，特别是癌症肽疫苗的最新临床试验。
